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ABSTRACT
Cryopreservation of stem cells after collection from peripheral blood or bone marrow for autologous trans-
plantation necessitates protection with dimethyl sulfoxide (DMSO). Unfortunately, DMSO, when infused with
the thawed cell suspension, may induce serious complications and side effects. To assess whether depletion of
DMSO before autografting affects safety and efficacy, 56 consenting consecutive patients treated with high-
dose chemotherapy and autologous blood stem cell transplantation were assigned to obtain either an untreated
or DMSO-depleted autograft. On the day of transplantation, the cryopreserved cells were thawed and infused
to the patient either immediately or after washing 3 times in normal saline supplemented with 6% anticoag-
ulant citrate dextrose solution. Cell count with viability, clonogenic assay, and phenotyping were performed
before and after thawing and after washing. Hematologic recovery, side effects, and complications were
recorded. The in vitro and clinical data on 56 patients show that the depletion of DMSO in vitro before
autografting does not induce a significant loss of cell number, viability, colony-forming unit–granulocyte-
macrophage activity, or number of CD34 cells. Furthermore, it leads to a safe and sustained engraftment. The
complications and side effects, as recorded by continuous monitoring, were substantially less; however, the
procedure takes 3 to 4 hours of laboratory work per patient.
© 2004 American Society for Blood and Marrow Transplantation
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SNTRODUCTION
High-dose chemotherapy (HDCT) and autolo-
ous blood stem cell (ABSC) transplantation are in-
reasingly used for the treatment of hematologic ma-
ignancies [1]. As part of bone marrow (BM) or ABSC
ransplantation, collected cells are frozen and stored
or prolonged periods. Because cells can be injured by
he direct effect of low temperatures and by the for-
ation of ice crystals, which then leads to cell dehy-
ration, a cryoprotectant is used to maintain cell in-
egrity. Ideally, a cryoprotectant should maintain the
uality of the collection product without causing any a
B&MTdverse effects to the recipient of the transplantation
r to the cells being preserved. Dimethyl sulfoxide
DMSO) is the cryopreservation agent most often
sed by transplantation centers. Although it is usually
elatively nontoxic to patients in small amounts, rein-
usion of solutions containing substantial volumes of
MSO has been associated with adverse effects (up to
0%) [2]. Sudden and severe hypotension can result
rom the intravenous (IV) infusion of DMSO, pre-
umably from histamine-induced vasodilation [2].
kin ﬂushing, dyspnea, abdominal cramping, nausea,
nd diarrhea can also be attributed to DMSO-induced
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1istamine release [3]. Other adverse effects associated
ith DMSO include headache, fever, hemolysis, en-
ephalopathy, and cardiovascular symptoms [4-8].
hese may result in increased morbidity, prolonged
ospitalization, and increased treatment-related costs.
o far, only a few reports [9-12] have investigated the
n vitro toxicity of DMSO on hematopoietic stem
ells. It has been postulated that DMSO can be toxic
o hematopoietic cells and BM stromal cells [13].
In view of the potential toxicities associated with
he administration of DMSO to patients, it may be
dvantageous to eliminate it from the autograft before
einfusion. This study compared cell quality and
uantity, engraftment kinetics, and adverse reactions
elated to the reinfusion of DMSO-depleted versus
MSO-containing autografts. This study was per-
ormed in patients who had received HDCT with
BSC transplantation for metastatic breast cancer in
n outpatient setting previously described by our
roup [14].
ETHODS
atients
Fifty-six patients receiving HDCT and ABSC
ransplantation for metastatic breast cancer were eval-
ated. All patients participated in a single-center study
n Sudbury. The institutional review board approved
he study. All patients signed informed consent. In-
luded in our study were patients between 18 and 55
ears old (median, 42 years) who had not had previous
hemotherapy for metastatic breast cancer. They had
valuable or measurable disease, and the disease either
rogressed with hormonal treatment or was hormone-
eceptor negative. No patients with central nervous
ystem metastasis were allowed on study. The ﬁrst 21
atients received an untreated autograft, whereas the
ollowing 35 had DMSO depletion before reinfusion
f their autograft. These were consecutive, consenting
atients.
hemotherapy Regimens and ABSC Collection
All patients underwent 3 to 4 cycles of induction
hemotherapy (IDC) with cyclophosphamide, doxo-
ubicin, and 5-ﬂuorouracil. A growth factor, recom-
inant human granulocyte colony-stimulating factor
rhG-CSF, Neupogen; Amgen Canada Inc., Missis-
auga, ONT), was administered subcutaneously (SC)
rom the day after IDC until the apheresis procedures
ere completed. When the white blood cell count
WBC) reached 2.5/nL and the platelet count was
0/nL, apheresis was performed daily on 4 consecu-
ive days as described previously [15]. Apheresis was
erformed with the Fenwal CS 3000 Plus blood sep-
rator (Baxter Healthcare Corporation, Deerﬁeld, IL).
total blood volume of 10 L per apheresis was pro- H
36essed at a ﬂow rate of 60 to 70 mL/min [15-17].
ollections were continued until a value of at least 2
06 CD34 cells per kilogram body weight was
eached. Each apheresis product (AP) obtained was
ryopreserved in 10% (vol/vol) DMSO and stored in
iquid nitrogen until the time of reinfusion [15]. The
DCT consisted of cyclophosphamide 6 g/m2 body-
urface area (BSA), mitoxantrone 70 mg/m2 BSA, and
ither carboplatin 800 mg/m2 BSA or vinblastine 12
g/m2 BSA, all administered IV. Then, 24 to 48
ours later, the autograft was reinfused, and recombi-
ant human granulocyte-macrophage colony-stimu-
ating factor (GM-CSF) or rhG-CSF at a dose of 5
g/kg body weight SC was administered until hema-
ologic recovery.
igh-Dose Chemotherapy
Only patients whose disease did not progress on
DC and who did not experience severe toxicity or
ajor organ damage proceeded to HDCT. HDCT
onsisted of cyclophosphamide 2 g/m2 IV, mitox-
ntrone 23.3 mg/m2 IV, and mesna 300 mg/m2 IV
very 8 hours. This was delivered on 3 consecutive
ays for a cumulative dose of cyclophosphamide 6
/m2 and mitoxantrone 70 mg/m2. Appropriate hy-
ration and premedications were administered. On
ay 4, the paclitaxel dose starting at 250 mg/m2 BSA
as delivered as a 3-hour IV infusion. Premedication,
ncluding dexamethasone at 20 mg by mouth, was
iven 12 and 6 hours before infusion, as was histamine
eceptor1 and histamine receptor2 antagonist therapy.
he 4 days of chemotherapy were administered in the
ospital. The patients were usually discharged from
he hospital for outpatient observation on the day after
DCT. After 48 hours of rest, the ABSC were rein-
used, and rhG-CSF was administered at 5 g/kg BW
C daily until hematologic recovery (absolute neutro-
hil count, 1.5  109/L).
andling of the AP before Reinfusion
With aseptic technique, the cryocyte freezing bags
Baxter Healthcare Corporation), each containing 94
L of cryopreserved AP, were removed from liquid
itrogen storage and rapidly thawed to just above
reezing in a 40°C water bath. They were then placed
n ice to maintain the temperature at 4°C. In the ﬁrst
1 consecutive patients, the AP was resuspended in
0-mL syringes and infused into a central line. In the
ext 35 patients, the following manipulations were
erformed aseptically at 4°C in a laminar ﬂow hood.
he following sterile wash solution was prepared in
dvance and was used for all washes: to a 1000-mL
.9% sodium chloride injection USP bag (Baxter
ealthcare Corporation), 60 mL of anticoagulant ci-
rate dextrose solution USP Formula A (Baxter
ealthcare Corporation) was injected. A Fenwal
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Depletion of DMSO before Autografting
Blasma transfer set with a spike and needle adapter
Baxter Healthcare Corporation) was inserted into the
ag to facilitate washes. This solution was then placed
n ice to maintain the temperature at approximately
°C. Each thawed AP was transferred from the cryo-
yte freezing bag into a 300-mL Fenwal transfer pack
ontainer with a sample site coupler inserted (Baxter
ealthcare Corporation). The transfer line was then
lamped, sealed with a hemostat, and cut. Each pack
as then ﬁlled with 150 to 200 mL of wash solution,
ently mixed, and centrifuged at 1200 rpm for 10
inutes at 4°C. The supernatants were then pressed
ff by using a Fenwal plasma extractor into a 2000-mL
ransfer pack container (Baxter Healthcare Corpora-
ion), into which a Fenwal plasma transfer set (Baxter
ealthcare Corporation) with a spike and needle
dapter had been inserted; the original line with spike
ad been sealed and cut off. The remaining cells were
ently resuspended and combined into one of the
ransfer packs by using a 60-mL syringe. Two addi-
ional washes, each consisting of 150 to 200 mL of the
ash solution, followed by centrifugation at 1200 rpm
or 10 minutes at 4°C, were performed. The cells were
hen resuspended in a volume of 40 to 60 mL of the
ash solution. A small sample was reserved for cell
ounts, clonogenic assay, and CD34 phenotyping.
he remainder was transferred into a 60-mL syringe
nd reinfused into the patient.
uality Assessment of the Autografts
The cell number was obtained through a manual
ethod by using a 0.2% Tu¨erks solution (Fluka
hemicals, Buchs, Switzerland) in a modiﬁed
eubauer chamber (Fluka Chemicals). Viability was
etermined with the trypan blue exclusion method
0.4% solution; Sigma Chemicals, St. Louis, MO).
he following antibodies were used for immunophe-
otyping of the cells with a Coulter Epics Elite cell-
orter analyzer (Fullerton, CA): anti-CD33 (Becton
ickinson, San Jose, CA), anti-CD34 (Becton Dick-
nson), and anti-CD38 (Becton Dickinson). Brieﬂy,
00 L of the cell suspension at a concentration of 106
ells per milliliter was incubated with 20 L of the
ppropriate monoclonal antibody for 20 minutes on
ce. Cells were washed in phosphate-buffered saline
ontaining 0.02% sodium azide (Sigma Chemicals),
able 1. In Vitro Results for Cell Quantity of the Reinfused Autograft*
Variable
DMSO-Containing
(n  21)
DMS
befor
(
NC ( 108/kg BW) 3.47 (2.1-5.89) 3.45
D34 (106/kg BW) 4.2 (1.22-21.1) 4.15
The ﬁrst column represents the 21 autografts reinfused after with
autografts that were evaluated before and after the washing procedure
B&MTnd 1% fetal bovine serum. Analysis regions were
ated on the total population according to the pub-
ished International Society of Hematotherapy and
raft Engineering guidelines [18].
A modiﬁed but standard clonogenic assay accord-
ng to the method described by Fauser and Messner
19] was used. In brief, 2 105 cells per milliliter were
lated into 30-mm suspension dishes (Life Technol-
gies, Grand Island, NY), which contained a semisolid
edium consisting of 2% methylcellulose (Shin-Etsu
hemical Company Ltd., Tokyo, Japan), Iscove-mod-
ﬁed Dulbeccas` medium supplemented with 26% fetal
ovine serum containing 2-mercapto-ethanol (4 
05 mol/L; Sigma Chemicals), recombinant human
nterleukin-3 (5 ng/mL), erythropoietin (2.5 U/mL),
nd recombinant human GM-CSF (10 ng/mL). The
ells were then incubated for 2 weeks in a humidiﬁed
tmosphere supplemented with 5% CO2. The result-
ng colony number was evaluated with an inverted
ight microscope. A colony was considered as con-
aining 50 cells. Colony-forming unit–culture
CFU-C), burst-forming unit, erythroid (BFU-E),
nd colony-forming unit–granulocyte, erythrocyte,
egakaryocyte, macrophage (CFU-GEMM) were
cored separately. Clonogenic assays were performed
n 20 of the 21 AP with DMSO and 20 new AP from
ew metastatic breast cancer patients whose product
as washed to remove the DMSO.
tatistical Analysis
Statistical analysis was performed with the com-
uter software SPSS (SPSS Inc., Chicago, IL). Statis-
ical signiﬁcance was reached if a P value of .05 was
btained. Continuous variables were analyzed with
he Student t test. No adjustments were made for
ultiple comparisons. Data related to toxicity were
nalyzed by the Mann-Whitney U test. This study
ould detect a difference in the time to obtain a WBC
0.5/nL of 2.5 days between the groups with a
robability of 90% ( error of .10), detecting an 
rror set at .05 [20].
ESULTS
To determine whether cell quality was similar
etween the groups, we ﬁrst examined cell number
eted
hing
)
DMSO-Depleted
after Washing
(n  35) % Loss
.9) 2.91 (0.8-9.1) 15.23  18.47 (0.1-54.5)
.3) 2.70 (0.4-19.5) 29.04  31.12 (0-79.2)
rther processing. The second and third columns represent the 35O-Depl
e Was
n  35
(1.3-12
(1.9-16
out fu
. Data are median or mean 	 SD (range).
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1nd viability. Table 1 summarizes the data for the cell
umber, viability, clonogenic cells, and CD34 cells
n both groups. The initial cell number was similar in
he 2 groups. After washing, there was a decrease in
he total mononuclear cell (MNC) count, but this was
ot signiﬁcant. Viability was 80% in all groups. The
ashing procedures showed a trend for total cell loss,
ut the differences between groups did not reach sta-
istical difference. The number of CD34 cells re-
ained equal in both the DMSO-containing and the
MSO-depleted prewash groups. There was a de-
rease in the number of CD34 cells after washing;
owever, this loss does not correlate with changes in
he time to engraftment.
When colonies were assessed, no difference was
ound in the number of BFU-E or CFU-GEMM;
owever, a small but signiﬁcant difference was found
n the number of CFU-C (Table 2). Despite this, the
edian hematologic recovery, deﬁned as a WBC
ount of 0.5/nL, occurred after 12 days (range, 8-15
ays) in the DMSO group, as compared with 11.0 days
range, 9-18 days) in the DMSO-depleted group (Ta-
le 3). A platelet count20/nL was reached in 11 days
range, 7-16 days) in the DMSO group as compared
ith 12 days (range, 7-24 days) in the DMSO-de-
leted group. The numbers of packed red blood cells
PRBC) and platelet transfusions were also compara-
le between groups. Patients in the DMSO group
able 2. Clonogenic Cells of the Washed AP and DMSO Containing
P: Comparison of Populations*
Colony
Type
DMSO-Containing
(n  20)
DMSO-Washed
(n  20)
P
Value
FU-C 63.95  76.3 (4-334) 25.6  29.9 (0-100) .043
FU-E 46.05  78.7 (0-356) 95.4  106.7 (2-382) .104
FU-GEMM 0.65  0.99 (0-4) 1.5  2.7 (0-11) .20
Data are mean 	 SD (range). Values represent the number of
colonies per 2  105 plated cells.
able 3. Data for the Comparison of Patients Who Had DMSO in
heir Autograft with Those Whose Product Was Washed before
ransplantation*
Variable
DMSO-
Containing
(n  21)
DMSO-
Washed
(n  35)
P
Value
ays to WBC 0.5  109/L 12 (8-15) 11 (9-18) .0455
ays to Plts 20  109/L 11 (7-16) 12 (7-24) .2599
ays to ANC 0.5  106/L 13 (9-17) 12 (9-19) .0242
nits of platelet transfusions 1.7 (0-6) 1.9 (0-6) .653
nits of packed red blood cell
transfusions 2.7 (0-6) 2.0 (0-12) .397
BC indicates white blood count; Plts, platelets; ANC, absolute
neutrophil count.
Mann-Whitney analysis was conducted for patients who had
DMSO in the reinfused autograft and those who had the wash-ding procedure before transplantation.
38eeded, on average, 1.7 platelet transfusions and 2.7
RBC transfusions, whereas the DMSO-depleted
roup needed 1.9 and 2.0 transfusions for platelets and
RBC, respectively. These differences were not sta-
istically signiﬁcant.
Patients in the DMSO group stayed, on average,
1.5 days in the hospital, compared with 19.3 days in
he DMSO-depleted group. This difference was not
tatistically signiﬁcant (P 
 .065). It is interesting to
ote that certain adverse effects tended to be less
requently observed in the DMSO-depleted group.
ausea, vomiting, and diarrhea occurred signiﬁcantly
ess often (P  .05) in the DMSO-depleted group
Table 4), whereas constipation tended to be more
ommon in the DMSO-depleted group (P 
 .051).
bdominal cramping, mucositis, fatigue, facial ﬂush-
ng, and discomfort (likely due to cyclophosphamide)
ere observed at similar frequencies in each group.
ebrile neutropenia was not observed more frequently
n the DMSO-depleted group. One patient in the
MSO group experienced a grade 4 hemorrhage. No
pisodes of sudden and severe hypotension, hemolysis,
r encephalopathy were observed in either group.
ne patient experienced a grade 2 cardiac adverse
vent in the DMSO group, whereas 1 patient experi-
nced a grade 1 cardiac adverse event in the DMSO-
epleted group. The patients with DMSO-depleted
utografts rarely complained of dry cough or tempo-
ary dysgeusia, in contrast to patients who received
ith unwashed autografts.
ISCUSSION
The use of a cryoprotectant is essential to main-
ain the viability and function of AP when it is stored
t very low temperatures. DMSO most often serves
his purpose in AP cryopreservation procedures. This
gent is selected for its relatively low toxicity in most
atients. Nevertheless, adverse effects as major as sud-
able 4. Side Effects and Complications within the First 12 Hours
fter Reinfusion of the Autograft*
Side Effect
DMSO-
Containing
(n  21)
DMSO-
Washed
(n  35)
P
Value
ash 5 0 .0037
bdominal cramps 11 0 <.0001
ack/bone pain 6 5 .160
ysgeusia 19 None, some
occasionally
<.0001
yspnea/cough 13 3 <.0001
acrohematuria/proteinuria 7 2 .0062
ardiovascular 10 7 .0297
HO indicates World Health Organization.
Numbers represent patients who experienced WHO grade 2 tox-
icities or more in each category (Fisher exact test).en and severe hypotension or encephalopathy, ob-
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Berved in recipients of ABSC transplants, have been
ssociated with DMSO. Further, the severity of ad-
erse reactions has been related to the amount of
MSO in the graft [21,22]. In the laboratory, the
uality of the autograft product is measured by the cell
iability, the total number of MNC, and the number
f CD34 cells. Clonogenic assay and immunophe-
otyping reﬂect committed and early progenitor cells.
linically, the quality of the autograft is reﬂected by
he time to hematopoietic engraftment. Some inves-
igators have assessed the in vitro effect of DMSO
ashing on the quality of autografts. Beaujean et al.
23] have described a DMSO-washing procedure used
n cryopreserved, thawed BM and AP grafts before
utologous transplantation. Their approach consisted
f a stepwise dilution with 2% human serum albumin
ollowed by centrifugation. In the 12 instances in
hich APs were involved, the mean recovery of MNC
nd colony-forming unit–granulocyte-macrophages
as 95.6% and 93.9%, respectively, with a mean cell
iability of90%. BM results were similar but slightly
ower. The differences between BM and AP recovery
ere not signiﬁcant. Menichella et al. [24] compared 2
ifferent procedures for BM processing. The ﬁrst one
nvolved hydroxyethyl starch as a sedimentary agent,
hereas the second one involved a semiautomated
rocedure with a blood cell processor (SteriCell; Du-
ont, Wilmington, DE). With both procedures,
NC and nucleated cell recovery, as well as red blood
ell removal, exceeded 80%. These investigators have
emonstrated that, by following their methods,
MSO can be washed from autografts without affect-
ng the quality of the leukapheresis products in vitro.
he next step is to compare the efﬁcacy and safety of
ashed versus unwashed grafts in the clinical setting.
ther components besides DMSO may be removed
y washing, some of which could be involved in the
ngraftment of the ABSC. In a previous, smaller
tudy, we showed sustained MNC numbers, viability,
nd CD34 subsets, as well as clonogenicity, after
ashing [25]. The cell numbers, viability, and compo-
ition did not change signiﬁcantly with the DMSO-
ashing procedure. More recently, one group has
escribed a novel washing/enzymatic digestion proto-
ol to remove DMSO from AP [26]. This study dem-
nstrated that the protocol was feasible, with no com-
lications related to the speciﬁc toxicity of reinfusion;
owever, they did not compare reinfusion of washed
ith unwashed AP, and, further, the use of deoxyri-
onuclease in a clinical setting may not be practical.
Our study was designed to evaluate whether
MSO could be depleted in vitro from AP collection
roducts without affecting its ability to restore the
ematopoietic system after HDCT in breast cancer
atients. As seen in Table 3, hematopoietic recovery
as similar between the group that received an ABSC
ollection product containing DMSO and the group e
B&MTn which DMSO had been depleted. The number of
ays to reach a WBC count greater than 0.5/nL and a
latelet count greater than 20/nL was not statistically
ifferent between groups and was comparable with
reviously published results. Transfusions were gen-
rally performed when the platelet count was less than
0/nL and the hemoglobin was less than 80 g/L. Here
gain, no difference in hematologic support was ob-
erved between groups.
Some small differences were encountered when
lonogenic assays were performed. The washed group
roduced signiﬁcantly less CFU-C than the group
ith DMSO. This was a small difference and likely
ot clinically relevant, because there were no differ-
nces in time to engraftment between groups. No
ifferences in BFU-E or CFU-GEMM were found
etween groups.
The second aspect of our evaluation concentrated
n the adverse effects experienced by our patients
Table 4). The main ﬁnding relates to nausea, vomit-
ng, and diarrhea, which were less intense and less
requent in patients in DMSO-depleted group. Cer-
ain adverse reactions were more difﬁcult to evaluate.
ome aspects of the GM-CSF toxicity proﬁle are
hared with DMSO, namely, fever and abdominal
ramping [27]. Abdominal cramps can occur early in
he course of GM-CSF administration, whereas fever
enerally occurs on hematopoietic recovery and has a
ecognizable pattern [27]. Fever related to GM-CSF
ould tend not to occur at the same time as the
einfusion of ABSC, whereas abdominal cramps are
ore difﬁcult to assign to a speciﬁc cause because the
rst dose of GM-CSF would occur within 24 hours of
BSC transplantation. Therefore, in view of the small
opulation size, the results are not sufﬁcient to elim-
nate the possibility of a difference in the incidence of
bdominal cramps between groups. Fever associated
ith neutropenia, mucositis, fatigue, facial ﬂushing,
nd discomfort (cyclophosphamide) are common after
course of intense chemotherapy. All were equally
istributed between groups. Because chemotherapy
egimens and the distribution of patients who received
ither G-CSF or GM-CSF during HDCT were sim-
lar between groups (data not shown), no link to those
ariables can be made. Febrile neutropenic episodes
ad no direct link to ABSC reinfusion. They occurred
ater after several days of neutropenia and could be
ttributed to bacterial infection or GM-CSF admin-
stration [27]. Before using CD34 selection methods,
ife-threatening adverse events due to DMSO toxicity
ere observed. In a recently presented study in which
D34-selected (and volume-reduced) autografting
as randomized compared with reinfusion of unma-
ipulated autografts, no differences in neutropenic
ecovery were observed, but the differences due to
MSO toxicity were statistically signiﬁcant [8]. This
xactly conﬁrms our observation. As we gained expe-
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1ience with the ABSC procedure, patients stayed in
he hospital for shorter periods of time. However, this
ransition occurred over a prolonged period of time.
resently, the transplantation procedure is performed
n an outpatient basis [14]. Therefore, in our center,
ospital stay is not a good indicator of the severity of
orbidity. Patients in the DMSO group had under-
one transplantation before the patients in the
MSO-depleted group. Therefore, eventually the pa-
ients who received a DMSO-depleted AP would be
ospitalized for a shorter period [28]. Of importance
s that nausea, vomiting, and diarrhea can be very
nconvenient to patients, and decreased morbidity as-
ociated with the reinfusion of ABSC can facilitate the
ransition of this procedure to the outpatient setting.
ne possible downside is that depleting AP of DMSO
akes between 3 and 4 hours of laboratory work per
atient. This can be a limiting factor, depending on
he laboratory facilities, staff support, and number of
ransplantations performed.
HDCT followed by peripheral blood stem cell
ransplantation was one of the promising approaches
o high-risk and metastatic breast cancer in the 1990s.
n 1999, several studies were presented that did not
how any beneﬁt in survival of these patients, and
oxicity became unacceptably high [29].
In conclusion, the depletion of DMSO in vitro,
efore autografting, did not prolong the time toWBC
nd platelet recovery, nor did it increase the necessary
ematologic support. Most importantly, morbidity re-
ated to the procedure was reduced. If laboratory sup-
ort permits, DMSO depletion of APs can be per-
ormed in vitro to decrease procedure-related
orbidity.
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